With international efforts to administer the Covid-19 vaccinations underway, a glaring disparity in the vaccine distribution has emerged. High-income countries, composing about 16% of the world’s population, have purchased approximately…
Tag: pharmaceuticals
in Access to Medicines, Commercialization, Design, Development, IP, Patentability, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
1105
What Makes It My Molecule: A Look at Professor Ronald Pearlman’s Genome Editing Work
This past November, Professor Ronald E. Pearlman from York University’s Department of Biology gave a talk [1] at Osgoode Hall Law School to discuss the potential of the innovative CRISPR…
IP Intensive Program: Experiential Learning at Actavis
My 10 week internship at Actavis’ Canadian arm (formerly known as Cobalt), through Osgoode’s IP Intensive Program coincided with a very exciting time for the company. The company recently expanded…
Canada v. GSK - Intellectual Property Rights and the Arm's Length Principle
In an eagerly anticipated decision, the Supreme Court of Canada released its judgment on Canada v. GlaxoSmithKline Inc., 2012 SCC 52 (Glaxo SCC, affirming 2010 FCA 201 [Glaxo FCA]). (more…)
Allergan Inc. c. Canada (Health), 2012 FC 767: Comity or Tragedy?
A somewhat confusing victory for Allergan Inc. was won on June 18th, as the Honourable Justice Hughes upheld their patent on COMBIGAN despite the fact that their invention was ruled…
India’s First Compulsory Licence: Patents vs Public Health?
In a move with far reaching implications for the debates around pharmaceutical patents, innovation and access to medicines, the Indian patent office issued its first ever compulsory licence in the…